{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"7"}],"units":"Participants"}],"description":"Will be tabulated and reported according to grade, type, cycle, and attribution.","groups":[{"description":"Patients receive recombinant EphB4-HSA fusion protein intravenously (IV) over 60 minutes on days 1 and 15. Patients also receive azacitidine IV or subcutaneously (SC) on days 1-7 or days 1-5 and 8-9, or decitabine IV on days 1-5. Administration of recombinant EphB4-HSA fusion protein occurs before or after the HMA (not concurrently). Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity.\n\nAzacitidine: Given IV or SC\n\nDecitabine: Given IV\n\nLaboratory Biomarker Analysis: Correlative studies\n\nPharmacological Study: Correlative studies\n\nRecombinant EphB4-HSA Fusion Protein: Given IV","id":"OG000","title":"Treatment (sEphB4-HSA, Azacitidine, Decitabine)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Tolerability was assessed by summarizing the number of participants who completed two courses of treatment without the occurrence of dose limiting toxicity and the ability to begin course 3 within 4 weeks","reportingStatus":"POSTED","timeFrame":"Up to 3 months","title":"Tolerability Defined as the Ability to Complete Two Courses of Treatment Without the Occurrence of Dose Limiting Toxicity and the Ability to Begin Course 3 Within 4 Weeks and Graded According to the NCI CTCAE v4.0","type":"PRIMARY","unitOfMeasure":"Participants"}